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Abstract: Introduction: Multiple sclerosis (MS) is one of the most common neurological disabling diseases in human so-
cieties with no complete cure. IFN-β has been proven to be an important advance in the MS treatment, but
early identification of treatment failure is its major concern. Some researches revealed that MxA is an appropri-
ate biomarker for predicting response to IFN-β, so we performed this study to evaluate the relationship between
MxA level and response to INF-β treatment. Methods: International and internal databases were searched using
“MxA”, “Myxovirus resistance protein A”, “IFN-β”, “interferon Beta”, “multiple sclerosis” and “MS keywords until
October 2019. Inclusion criteria were original studies considering the MxA assays in MS patients under IFN-β
therapy. Some reported cut-offs from partially the same settings (7 studies) were pooled using the weighted av-
erage. Finally, the overall statements of the included studies were compared and discussed to obtain a compre-
hensive conclusion about the clinical value of MxA assays in patient monitoring and designing their treatment
plan. Results: A total of 456 articles were identified. The Screening was led to exclusion of 427 articles. Finally,
28 original studies met the inclusion criteria for this systematic review. Almost all studies have concluded that
the MxA is significantly correlated with response to IFN-β therapy and also MxA expression is under the direct
effect of Neutralizing antibody (NAb) against IFN-β. Reported cut-offs for MxA ranged from 3.3 to 6.3 NR and the
weighted average of them was estimated to be 4.1 NR. Conclusion: It could be suggested that in patients under
IFN-β therapy with an active disease which doesn’t fulfill the criteria for the breakthrough disease, MxA level can
help to determine whether to continue the drug and follow up a patient or change the treatment regimen.
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1. Introduction
Multiple Sclerosis (MS) is a disabling disease that may cause
weakness, loss of vision, imbalance, urinary incontinence,
and sensory symptoms (numbness and paresthesia) by af-
fecting the brain and spinal cord. Destruction of myelin (de-
myelination) in MS patients, causes a slowing of nerve im-
pulses, or conduction block to produce the common symp-
toms of this disorder. According to the involvement of
400,000 people in the United States and 2.1 million world-
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wide, MS is one of the most common neurological diseases
in human societies [1].
Although there is no drug for the complete cure of MS but
treatment and care can help to reduce its attacks and pro-
gression. Viral infections have been hypothesized as an envi-
ronmental susceptibility factor for multiple sclerosis [2]. In-
terferons are molecules in the body that raise the anti-viral
defenses of cells, so they can be used against them as a treat-
ment method. The three main types of known interferon in-
clude alpha, beta, and gamma interferons based on antiviral
effect, anti-growth, and activation of natural killer cells. IFN-
β is a 166-amino-acid glycoprotein with a complex three-
dimensional structure consisting of five a-helices, a disul-
fide bond (between cysteine 31 and 141) and a glycosylation
site (at asparagine 80) which is approved by FDA for treating
MS and nowadays recombinant interferon-beta (IFN-β) with
some differences compared to the natural form is produced
[3, 4].
IFN-β can have its effect to reduce the immune response that
is directed against myelin in the central nervous system in
people with MS [3]. Nevertheless, IFN-β has proven to be an
important advance in the MS treatment and its therapeutic
possibilities are expanding, but early identification of treat-
ment failure is its major concern, so the determination of
optimal markers to predict its clinical effectiveness and also
evaluating its bioavailability, seems to be necessary [5].
Bioavailability determinates clinical efficacy by representing
the amount of drug that interacts with specific cells which
are involved in clinical action. The bioavailability of IFN-β
can be evaluated by quantifying drug levels or by measuring
IFN induced proteins (e.g., neopterin or myxovirus resistance
protein 1[MxA]) released by cells involved in the therapeutic
effect [6]. And also by detecting the binding and neutralizing
components such as antibodies and soluble receptors. Neu-
tralizing antibodies (NAb) are induced against IFN-β and as
a result, they can reduce treatment efficacy in patients with
multiple sclerosis [7].
The human MxA by its ability to self-assemble into highly or-
dered oligomers and forming ring-like structures around li-
posomes, induces liposome tubulation and acts as a key me-
diator of the interferon-induced antiviral response against
a wide range of viruses. According to the results lots of re-
searches in this field, MxA gene expression evaluation is one
of the most appropriate methods for measuring the biologic
activity of exogenous IFN-β, so may be useful for predict-
ing whether multiple sclerosis patients will respond or not to
interferon-β treatment [6, 8].
The aim of this study was to determine the importance of in-
vestigating MxA gene or protein changes in MS patients un-
der interferon therapy and its correlation with other determi-
nants of IFN bioavailability (e.g. NAb), and also the effect of
gender, age, and response rate, by reviewing previous studies
in this field as described below.
2. Methods
As mentioned the purpose of this study was to figure out all
scientific knowledge about the MxA evaluation methods and
its value as a biomarker of IFN-β therapy in patients with
Ms. Regarding this topic, the study eligibility was defined as
all types of studies (cross-sectional, prospective and Cohort
studies) reporting the values and methods of MxA assay in
MS patients receiving IFN-β. International databases includ-
ing MedLine, Scopus, Web of Science and ProQuest, and na-
tional databases including scientific information databases
(SID) from inception until October 2019 were searched us-
ing the following keywords: “MxA”, “Myxovirus resistance
protein A”, “IFN-β”, “interferon Beta”, “multiple sclerosis”,
and “MS”. No language restriction was defined and eligi-
ble studies could have been published in either English or
Farsi. Inclusion criteria were original studies (including all
cross-sectional, longitudinal, Cohort, and prospective stud-
ies) considering the MxA gene expression or protein assays
in MS patients under IFN-β therapy. Studies about MxA gene
polymorphism or promotor as well as studies with no full text
available or short commentaries were excluded. The Process
of selecting articles was completed by two independent re-
searchers. Extracted data were entered into a table which in-
cluded bibliographic information of studies (author‘s name,
publication year, and type of study), study design (partici-
pants, conducted tests, follow up duration), and main study
achievement about the MxA evaluation in MS patients such
as significant association with clinical findings, cut-offs, Haz-
ard Ratios, etc. Due to the wide variety of reported data
across studies, the meta-analysis was not applicable. Nev-
ertheless, some reported cut-offs from partially the same set-
tings were pooled using the weighted average based on the
study’s sample size, so an amount from a study with a greater
sample size would have a greater effect on the final average.
All the quantitative part was performed by Microsoft Excel
spreadsheets. Finally, the overall statements of the included
studies were compared and discussed to obtain a compre-
hensive conclusion about the clinical value of MxA assays in
patient monitoring and designing their treatment plan.
3. Results
At the initial searching phase, 456 articles were retrieved. The
Screening was initially done on study titles which led to ex-
clusion of 321 articles. Additional 8 articles were excluded
due to studying polymorphisms of MxA gene and its promo-
tor and also if they were not original studies. Finally, 28 orig-
inal studies met the inclusion criteria for this systematic re-
view (Figure 1).
As the time-based sorted table 1, reviewing included stud-
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ies revealed that the MxA quantification in MS patients was
started from the late 90s, early focused on MxA protein de-
tection and then changed to MxA gene expression assays.
Almost all studies have concluded that the MxA is signifi-
cantly correlated with response to IFN-β therapy and also
MxA expression is under the direct effect of neutralizing an-
tibody (NAb) against IFN-β. But binding antibody (BAb) was
reported to has either no association or less likely to corre-
late with MxA and therapeutic responses in MS. Some studies
also showed that the baseline MxA level can predict the pa-
tient’s response to IFN-β. There is a dose-response between
MxA and EDSS score, reported by one study. Seven stud-
ies have reported a cut-off for MxA gene expression by the
unit of Normalized Ratio (NR) which was equal to 2–∆∆Ct,
∆∆Ct= (The difference between the ∆Ct [Cycle threshold] of
the sample and the ∆Ct of the calibrator) and ∆Ct= (Ct of
MxA for each sample minus Ct of GAPDH). Reported cut-offs
are ranging from 3.3 to 6.3 NR and the weighted average of
them estimated to be 4.1 NR. So it could be concluded that
patients with MxA≥4.1 are responsive to IFN-β therapy as
they are considered to have acceptable IFN-β bioactivity or
MxA induction. Four studies have used a titer of 20 NU/ml
(NAb>20 TRU) as a cut-off for NAb positivity. One study has
taken 100 TRU and one study has reported 150 TRU as a com-
plete loss of bioavailability of IFN-β. BAb is not as sensitive
as NAb and estimated to have no significant clinical value by
several studies.
4. Discussion
Since measurement of anti-interferon antibodies can deter-
mine the bioavailability of IFN-β and there is a strong asso-
ciation between antibody development and MxA reduction,
in some cases the presence of a soluble IFN-β receptor can
bind to the injected interferon and lower its bioavailability
and we will see the un-responsiveness to treatment and also
no MxA induction despite the low level of anti-interferon an-
tibody. Therefore, measuring MxA is more useful than mea-
suring antibodies alone. In fact, the presence of antibodies
can predict the poor response to treatment, but its negative
results require to be confirmed by MxA measurement.
As shown in one included study women older than 30 years
up to 40 years may be more susceptible to lose their MxA in-
duction that might be due to different NAb response as a re-
sult of sex hormone and the difference in immune response
in men and women [10]. Also, the type of INF-β used in the
treatment regimen is effective in antibody response and it
is demonstrated that using IFN-β1b is associated with more
antibody formation comparing with IFN-β1a which might be
a result of mild receptor desensitization [28]. Pachner in 2009
stated that the antibody formation against IFN-β is transient
and the bioavailability can be restored when NAb declined
and the European Union task force on NAbs says that all pa-
tients treated with interferon should be checked for NAb in
the first 24 months after treatment [24].
As mentioned in the results, if neutralizing antibody against
injected IFN-β increased to 20 TRU or more these patients
are showing some sort of un-responsiveness to IFN-β ther-
apy and should undergo closer monitoring. But NAb more
than 100 or 150 TRU mean that these patients have com-
pletely lost the INF-β bioavailability and the treatment esca-
lation may be considered for them.
Garcia-Montojo M., et al. in 2010 discussed MxA role in
the evaluation of MS treatment efficiency and their results
showed no significant correlation with NAb and clinical pa-
rameters (relapse, progression, and response)[19]. Their re-
sults were close to Deisenhammer F., et al., achievement
in 1999 witch confirm no significant difference of MxA
(cut-off=1.59 ng MxA/105 Leukocytes) between NAb-positive
(≥20 IU/ml) samples and control subjects and BAb however,
do not appear to influence the bioavailability of IFN-β1b [35].
In contrast, Gilli F., et al., in 2006 highlighted the important
role of MxA as the most sensitive gene to detect decreased
bioavailability due to NAbs [29] and Hesse‘s study concluded
that the inability of IFN-β to induce MxA expression (cut-
off =5 NR) in NAb-positive patients (TRU>20) equals a com-
pletely blocked biologic response [23].
According to Bertolotto A., et al., the MxA gene expression as-
say is superior to MxA protein assessments because that the
MxA protein levels could be affected by different interferon
doses, but MxA mRNA is less affected [33].
Finally, an important use of MxA assay in clinical practice
may be in making a decision on treatment in MS patients
with evidence of clinical and/or radiological disease activ-
ity not fulfilling criteria for breakthrough disease especially
those with minor relapses or minimal disability. The Break-
through disease in MS is defined as patients with clinically
active disease [≥1 relapse and/or disability progression] and
≥ 2 active MRI lesions [Gadolinium (Gd) Enhancing and/or
T2 Weighted], or in patients with severe relapses or ≥3 ac-
tive lesions) which their treatment needs to be escalated to
more potent drugs [36]. In these type of patients (with some
evidence of disease activity but not fulfilling the criteria of
the breakthrough diseases) MxA<4.1 shows that they are not
about to have a good response to IFN-β and may need early
escalation. But MxA≥4.1 means that these patients are tak-
ing advantage form INF-β therapy and should undergo close
monitoring.
5. Conclusion
MxA level (both the gene expression level and the protein)
is significantly correlated with treatment response to IFN-β
therapy. It could be suggested that in patients under IFN-β
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therapy with an active disease which doesn’t fulfill the criteria
for the breakthrough disease (i.e. those with minor relapses
or minimal disability and <2 active MRI lesion or patients
with <3 active lesions in MRI) MxA assay (with the priority of
gene expression assays) may give a determining checkpoint
to make a decision about their treatment plan with more con-
fidence to determine whether to continue the drug and fol-
low up the patient or change the treatment regimen.
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Figure 1: Flow diagram of studies on MxA assay in MS patients undergoing IFN-β therapy.
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Table 1: Summary of included studies about MxA evaluation in patients under IFN-β therapy.(Continuous)
First Author [Ref.] Study setting Overall Statement about MxA in
IFN therapy of MS
Study type
Fattahi M.,et al.,2019 [9] RT-PCR for MxA in 35 responders
and 35 non-responders RRMS
patients after 1 y IFN-β therapy
MxA Significantly increased by 8
fold in the responders (No in-
crease in the EDSS and no re-
lapse)
Cross sectional
Taheri M., et al., 2017[10] Quantitative RT-PCR for MxA in
50 RRMS patient and 50 healthy
controls
MxA Significantly decreased in
females > 30 up to 40 y (3 fold)
compared with healthy controls.
There is a gender bias in the re-
sponse to IFN-β therapy
Cross sectional
Matas E., et al., 2016[11] RT-PCR for MxA in 104 RRMS pa-
tients at baseline and after 1 y
IFN- β therapy
Next relapse was significantly
longer in the MxA>5 fold group
(2.8 y vs. 1.3 y)
Cohort
Matas E., et al., 2016[12] RT-PCR for MxA in 104 RRMS pa-
tients at baseline and after 3 m
and 12 m IFN- β therapy
High baseline MxA (RE>1.096),
and low MxA induction (<5 fold
increase) have a higher probabil-
ity of non-responding to IFN- β
Cohort
Juntunen E., et al., 2016[13] LFIA and ELISA for MxA in 36
samples from patients receiving
IFN-β-therapy for MS
LFIA Detects 96% of the IFN-β
responders with 89% specificity
(cut-off=100 µg/L) and is more
rapidly than ELISA
Cross sectional
Matas E., et al., 2014[14] RT-PCR for MxA in 104 RRMS pa-
tients at baseline and follow up
them for 2 y
Baseline MxA expression was
significantly lower in responders
(RE: 1.07 vs 1.95), (Cut-off = 1.096
RE)
Cohort
Cakal B., et al., 2014[15] RT-PCR for MxA & ELISA for BAb
in 128 MS patients under >3.6 y
IFN-β therapy
MxA bioactivity lost (NR≤4) in
82.5% of patients having >500
BTU BAb “sc IFN-β1b” caused
the highest seropositivity ratio
)70.4%( vs (28.6% in “sc IFN-
β1a”) and (21.4% in “im IFN-
β1a” )
Cross sectional
Serana F., et al., 2014[16] RT-PCR for MxA & RIPA for BAb
& CPE assay for NAb in 118
RRMS patients under 3 y IFN-β
therapy
Each 1-unit increase in the “av-
erage” log2MxA levels predicts a
reduction of 47% in the risk of
1-point EDSS increase BAb level
was higher in patients receiving




Hermanrud C., et al., 2014[17] RT-PCR for MxA and iLiteTM
(type I IFN responsive reporter
gene cell assay) for NAb in 44 MS
patients
MxA expression was greatly
reduced or blocked in pa-
tients with NAb titer above 150
TRU/mL
Prospective
Malucchi S., et al., 2011[18] RT-PCR for MxA & ELISA for BAb
& CPE assay for NAb in 167 MS
patients under 1 y IFN-β therapy
MxA Significantly decreased in
patients with NAb >100 TRU/ml
and BAb>8 U
Cross sectional
Garcia-Montojo M., et al.,
2010[19]
Quantitative PCR for MxA & CPE
assay for NAbs in 50 RRMS pa-
tients during 2 y IFN-β therapy
MxA had No significant cor-




Zanotti C., et al., 2010[20] Quantitative RT-PCR for MxA in
500 MS patient over a 4 y
MxA assay (cut-off=3.83 NR) is
reproducible and serves as an al-
ternative to NAb determinations
for use in routine clinical prac-
tice
Prospective
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Table 1: Summary of included studies about MxA evaluation in patients under IFN-β therapy. (Continuous)
First Author [Ref.] Study setting Overall Statement about MxA in
IFN therapy of MS
Study type
Van der Voort L. F., et al., 2010[21] RT-PCR for MxA and MRI in 116
RRMS at baseline and 2 y follow
up
higher baseline MxA (cut-
off=0.075 RE) is significantly
associated with longer time to
first relapse (HR=0.59), lower
relapse, and lower enhancing
lesion in MRI
Prospective cohort
Van der Voort L. F., et al., 2009[22] RT-PCR for MxA in 126 RRMS
under >6 m IFN-β therapy, re-
test after 3 m
Non-responders (MxA< 0.2 NR
and <3 fold increase at re-test)
showed a higher relapse rate sig-
nificantly
Prospective
Hesse D., et al., 2009[23] Screening for IFN-β-regulated
genes in 12 MxA+/NAb- and 12
MxA- /NAb+ MS patients
The Inability of IFN-β to in-
duce MxA expression (cut-off =5
NR) in NAb+ patients (TRU>20)
equals a completely blocked bi-
ologic response
Cross sectional
Pachner A.R, et al., 2009[24] RT-PCR for MxA & ELISA for BAb
& CPE assay for NAb & MRI for
lesion occurrence in 36 RRMS
patients under IFN-β therapy
In the preserved bioactivity
group (NAb≥20 TRU and MxA>
6.3 NR) “enhancing lesion/scan
ratio” decreased 66% in the
post-treatment period.
Prospective
Millonig A., et al., 2008[25] Serial ELISA for MxA and NAb in
20 PPMS under IFN-β1b therapy
in 1 y
The mean area under the curve
of log MxA levels during treat-
ment was significantly higher in
stable patients than in progress-
ing patients
Prospective
Vallittu A.M., et al., 2008[26] EIA and flow cytometric for MxA
in 51 RRMS under IFN-β therapy
EIA (cut-off =100 µg ⁄ l) was fa-
vorable and more sensitive com-
pared with the flow cytometric
Cross sectional
Malucchi S., et al., 2008[27] RT-PCR for MxA & ELISA for BAb
& CPE assay for NAb in 137 MS
patients after 1 y IFN-β therapy
MxA- (<87 RE) or NAb+ (>20
TRU) patients showed poorer
RFS (HR=2.87, HR=2.49), BAb
was not significant. MxA had a
slightly stronger prognostic sig-
nificance
Prospective 3 y follow-up
Capra R., et al., 2007[28] RT-PCR for MxA & RIPA for BAb
& CPE assay for NAb in 99 MS pa-
tients after >2 y IFN-β therapy
Anti-IFNβ antibodies well cor-
related with MxA induction loss
(Cut-off=3.82 NR) Mean MxA
was significantly lower in pa-
tients under “sc IFN-β1b” in
comparison to “im IFN-β1a”
Cross sectional
Gilli F., et al., 2006[29] Quantitative-PCR for Mxa,
TRIAL, XAF-1, and CPE for NAb
im 73 RRMS patients
MxA was the most sensitive gene
to detect decreased bioavailabil-
ity due to NAbs
Cross sectional
Pachner A. R., et al., 2005[30] RT-PCR for MxA & ELISA for BAb
& CPE assay for NAb in 64 RRMS
patients under IFN-β therapy
-IFN-β1a caused the lowest ADB
-ADB is a reversible condition
MxA assay (Cut-off =6.3NR) is a
valuable adjunct for monitoring,
especially when the antibody is
substantial
Prospective
Bertolotto A., et al., 2004[31] 5 days RT-PCR for MxA (every 3
m) & CPE assay for NAb in 62
RRMS patients under different
IFN-β regimen
Higher biological responses
(MxA≥ 0.132 RE) and higher risk
for NAb (≥20 TRU) were seen
in patients treated three times
a week (Betaferon and Rebif)
instead of once (Avonex)
Prospective
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Table 1: Summary of included studies about MxA evaluation in patients under IFN-β therapy.
First Author [Ref.] Study setting Overall Statement about MxA
in IFN therapy of MS
Study type
Pachner A. R., et al., 2003[5] RT-PCR for MxA & ELISA for BAb
& CPE assay for NAb in 68 RRMS
patients under IFN-β therapy
First report of RT-PCR for MxA
as IFN-β biomarker (non-
responder<3.3 NR) The Best
strategy is to monitor with BAb
and then RT-PCR for MxA in
BAb+ individuals
Prospective
Vallittu A. M., et al., 2002[32] Flow cytometric for MxA &
ELISA for BAb & CPE assay for
NAb in 20 RRMS patients under
1 y IFN-β1a therapy
The Presence of NAb does not
necessarily inhibit the biologic
effects of IFN-β, MxA protein in
lymphocytes is promising as an
additional marker
Prospective
Bertolotto A., et al., 2001[33] qc-PCR for MxA & CPE assay for
NAb in 48 RRMS patients before
and after IFN-β
Bioavailability of the three avail-
able types of IFN-β can be eval-
uated by MxA qc-PCR
Cross sectional
Kracke A., et al., 2000[34] ELISA for MxA in 52 RRMS pa-
tients under IFN-β1b therapy
MxA levels were significantly
lower during relapse (Median:
11.2 mU/1,000 Leukocytes)
than during stable phases (20.5
mU/1,000 Leukocytes) and
within the first month after




Deisenhammer F., et al.,
1999[35]
ELISA for MxA and BAb & MxA
induction assay for NAb in 134
MS patients under IFN-β1b
therapy and 54 control
- There was no significant dif-
ference of MxA (cut-off=1.59 ng
MxA/105 Leukocytes) between
NAb+ (≥20 IU/ml) samples and
control subjects - BAb, however,
do not appear to influence the
bioavailability of IFN-β1b
Cross sectional
RT-PCR: Reverse Transcriptase-Polymerase Chain Reaction, PPMS: Primary progressive multiple sclerosis,
RRMS: Relapsing-Remitting Multiple Sclerosis, EDSS: Expanded Disability Status Scale, RFS: Relapse-free survival,
ADB: Antibody-mediated Decreased Bioactivity, Activity, NR: Normalized Ratio, BTU: Bühlmann Titer Units, TRU: Tenfold Reduction
Units, BAb: Anti IFN- β Binding Antibody, NAb: Anti IFN- β Neutralizing Antibody, RIPA: Radio immunoprecipitation Assay,
SC: subcutaneous, IM: intramuscular, ELISA: Enzyme-Linked Immunosorbent Assay, CPE: Cytopathic Effect,
EIA: Enzyme immune assay, LFIA: Lateral Flow Immunoassay, RE: Relative Expression (Expression levels relative to GAPDH
expression levels), Y: year, m: month, MRI: magnetic resonance imaging.
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